SNX-5422
|
|
|
- CAS号:
- 908115-27-5
- 英文名:
- PF-04929113
- 英文别名:
- CS-33;SN-5422;snx54227;SNX-5422;SNX-5542;SC-102112;SC-105422;SC-107881;PF-4928473;PF-4929113
- 中文名:
- SNX-5422
- 中文别名:
- 化合物PF04929113;PF-04929113 5mg试剂;PF-04929113 5mg试剂;化合物PF04929113,10 MM DMSO 溶液;PF-04929113(SNX-5422),HSP90抑制剂;PF-04929113 (SNX-5422) 10mM * 1mL in DMSO试剂;PF-04929113 (SNX-5422) 10mM * 1mL in DMSO试剂;甘氨酸反式-4-[[2-(氨基羰基)-5-[4,5,6,7-四氢-6,6-二甲基-4-氧代-3-(三氟甲基)-1H-吲唑-1-基]苯基]氨基]环己酯;反式-4-((2-氨基甲酰基-5-(6,6-二甲基-4-氧代-3-(三氟甲基)-4,5,6,7-四氢-1H-吲唑-1-基)苯基)氨基)环己基 2-氨基乙酸酯;PF-04928473;PF-04929113;SC-102112;SC-105422;SC-107881;PF-4929113;SNX-2112;PF-4928473;SN-5422;SNX-5422;SNX-5542
- CBNumber:
- CB52561489
- 分子式:
- C25H30F3N5O4
- 分子量:
- 521.53
- MOL File:
- 908115-27-5.mol
|
|
|
SNX-5422化学性质
-
熔点:
-
298-299℃
-
|
-
沸点:
-
646.5±55.0 °C(Predicted)
-
|
-
密度:
-
1.48
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
≥23.85 mg/mL in DMSO with gentle warming; insoluble in H2O; insoluble in EtOH
-
|
-
酸度系数(pKa):
-
15.07±0.50(Predicted)
-
|
-
形态:
-
solid
-
|
-
颜色:
-
White to off-white
-
|
SNX-5422性质、用途与生产工艺
PF-04929113 (SNX-5422)是一种有效的，选择性的HSP90抑制剂，Kd为41 nM，且诱导Her-2降解，IC50为37 nM。Phase 1/2。
| Target | Value |
HER2
()
|
37 nM
|
HSP90
()
|
41 nM(Kd)
|
PF-04929113是小分子Hsp90抑制剂。PF-04929113转化为SNX-2122起作用, SNX-2122是 Hsp90抑制剂的活性形式。PF-04929113有效作用于Her-2 稳定性，也引起Hsp70上调。PF-04929113作用于一系列癌细胞类型，具有有效的抗增殖活性。MCF-7(IC50=16 nM), SW620(IC50=19 nM), K562(IC50=23 nM), SK-MEL-5(IC50=25 nM), 及 A375(IC50=51 nM)。
PF-04929113处理小鼠，在体内抑制人类MM 细胞生长,免疫组化分析显示PF-04929113显著抑制p-ERK和p-AKT。同时, PF-04929113处理显著降低 CD31 免疫组化分析表明PF-04929113处理，提高SP70表达，和降低Ki67,Akt,和AR表达。降低增殖率(降低Ki67和Akt表达)或促进凋亡率(增加 ApopTag染色)可能导致PF-04929113抑制肿瘤进展。
SNX-5422
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2025/09/19 | S2656 | SNX-5422
PF-04929113 (SNX-5422) | 908115-27-5 | 5mg | 2211.02元 |
| 2025/09/19 | S2656 | SNX-5422
PF-04929113 (SNX-5422) | 908115-27-5 | 10mg | 3834.51元 |
908115-27-5, SNX-5422 相关搜索:
N-(3-氯苯基)-N'-[5-[2-(噻吩并[3,2-D]嘧啶-4-基氨基)乙基]-2-噻唑基]脲 4-氨基1-叔丁基-3-(1'-萘甲基)吡唑并[3,4-D]嘧啶 BLU9931 ZLN-005 埃索美拉唑镁 N-[2-[[4-[2-(6,7-二甲氧基-3,4-二氢-1H-异喹啉-2-基)乙基]苯基]氨基甲酰基]-4,5-二甲氧基苯基]喹啉-3-甲酰胺 帕布昔利布（palbociclib） 伊沙匹隆 L-4-噻唑丙氨酸 伊洛马司他 AZD1208 [1-[2-[5-(3-甲基氧杂环丁烷-3-基甲氧基)苯并咪唑-1-基]喹啉-8-基]哌啶-4-基]胺 盐酸多柔比星 司美替尼 BIIB021/CNF2024 SNX-2112;4-(6,6-DIMETHYL-4-OXO-3-(TRIFLUOROMETHYL)-4,5,6,7-TETRAHYDRO-1H-INDAZOL-1-YL)-2-((1R,4R)-4-HYDROXYCYCLOHEXYLAMINO)BENZAMIDE 奎扎替尼 盐酸芬戈莫德
- Inhibitor
- Inhibitors
- 药靶配体
- 抑制剂
- 小分子抑制剂，天然产物
- 细胞骨架信号
- 小分子抑制剂
- C25H30F3N5O4
- PF-04929113 5mg试剂
- PF-04929113 (SNX-5422) 10mM * 1mL in DMSO试剂
- PF-04929113 5mg试剂
- PF-04929113 (SNX-5422) 10mM * 1mL in DMSO试剂
- PF-04928473;PF-04929113;SC-102112;SC-105422;SC-107881;PF-4929113;SNX-2112;PF-4928473;SN-5422;SNX-5422;SNX-5542
- 化合物PF04929113,10 MM DMSO 溶液
- PF-04929113(SNX-5422),HSP90抑制剂
- 反式-4-((2-氨基甲酰基-5-(6,6-二甲基-4-氧代-3-(三氟甲基)-4,5,6,7-四氢-1H-吲唑-1-基)苯基)氨基)环己基 2-氨基乙酸酯
- 化合物PF04929113
- 甘氨酸反式-4-[[2-(氨基羰基)-5-[4,5,6,7-四氢-6,6-二甲基-4-氧代-3-(三氟甲基)-1H-吲唑-1-基]苯基]氨基]环己酯
- 908115-27-5
- SNX-5542
- SN-5422
- SC-107881
- SC-105422
- SC-102112
- PF-4929113
- PF-4928473
- PF04929113, 10 mM in DMSO
- PF-04929113 SNX-5422 PF04929113 SNX5422
- trans-4-((2-Carbamoyl-5-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)phenyl)amino)cyclohexyl 2-aminoacetate
- PF-04929113 USP/EP/BP
- snx5422 PF 04929113
- trans-4-([2-(Aminocarbonyl)-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl] phenyl]amino)cyclohexyl glycinate
- Glycine trans-4-[[2-(aminocarbonyl)-5-[4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl]phenyl]amino]cyclohexyl ester
- PF-04929113(SNX5422)
- SNX-5422
- PF-04929113
- PF04929113 SNX-54227
- snx54227
- PF-04929113, >=98%
- (1r,4r)-4-(2-carbamoyl-5-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydroindazol-1-yl)phenylamino)cyclohexyl 2-aminoacetate
- (1r,4r)-4-((2-carbamoyl-5-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)phenyl)amino)cyclohexyl 2-aminoacetate
- SNX5422;PF 04929113;SNX 5422;PF-04929113;
- CS-33